Evidence map›Paper›PMID 41377994›Full record

ArticleResearch square2025

Correlations of CSF Biomarkers of Alzheimer's Disease with Cognitive Measures in MCI and AD Dementia: A Cross-Sectional Analysis.

Gabriel Bitar, Sierra Alban, Kassu Beyene, Boris Decourt, Shervin Harirchian, Marwan N Sabbagh

Abstract readPreprint
In one paragraph

Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gabriel BitarCreighton University School of Medicine.
Sierra AlbanCreighton University School of Medicine.
Kassu BeyeneBarrow Neurological Institute.
Boris DecourtTexas Tech University Health Sciences Center.
Shervin HarirchianCreighton University School of Medicine.
Marwan N SabbaghBarrow Neurological Institute.

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Research Education ComponentP30AG019610 · NIA · SUN HEALTH RESEARCH INSTITUTE · PI REIMAN, ERIC MICHAEL · 2001 to 2020
$32.5M
MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI PatientsR01AG059008 · NIA · ST. JOSEPH'S HOSPITAL AND MEDICAL CENTER · PI DECOURT, BORIS, SABBAGH, MARWAN NOEL · 2018 to 2023
$3.6M
Repurposing Siponimod for Alzheimer's DiseaseR01AG073212 · NIA · ST. JOSEPH'S HOSPITAL AND MEDICAL CENTER · PI Boris Decourt, MARWAN Noel SABBAGH · 2021 to 2026
$2.8M
NIA NIH HHS P30 AG019610NIA NIH HHS R01 AG059008NIA NIH HHS R01 AG073212NIA NIH HHS U01 AG024904
6 · The paper itself

Abstract

Background and Objectives: We examined the relationships between cerebrospinal fluid (CSF) amyloid-β, tau, p-tau, and cognition in an Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset. Studies have examined the longitudinal relationships between CSF biomarkers for Alzheimer's disease (AD) and cognition, but there is discordance in the strength of associations between CSF amyloid-β, t-tau, or p-tau with cognition at different disease stages. Methods: The study included 665 patients from the combined ADNI dataset: 128 cognitively normal (CN), 175 with mild cognitive impairment (MCI), and 362 with AD dementia. All patients were amyloid-β-positive according to established CSF amyloid-β cut-off values. Cognitive assessments, diagnoses, and specimen collection/processing were conducted via published standardized protocols. We examined cross-sectional baseline data and performed correlational and regression analyses to evaluate the associations between CSF biomarkers and assessments of learning, memory, executive function, language, attention, visuospatial skills, and activities of daily living. Results: In the MCI cohort, significant negative correlations were observed between CSF amyloid-β and ADAS-Cog11 (r=-0.164, p=0.02, ADAS-Cog13 (r=-0.181, p=0.01), Trails B (r=0.11, p=0.04), and FAQ (r=-0.131, p=0.01). There were positive correlations between amyloid-β and MMSE (r=0.149, p=0.004) and amyloid-β and WMS-delayed recall (r=0.116, p=0.03). Statistically significant correlations were observed between CSF t-tau and p-tau and CDRSB (t-tau: r=0.105, p=0.047), ADAS-Cog11 (t-tau: r=0.114, p=0.03; p-tau-181: r=0.114, p=0.03), ADAS-Cog13 (t-tau: r=0.165, p=0.002; p-tau-181: r=0.162, p=0.002), RAVLT-forgetting (t-tau: r=0.173, p=0.001; p-tau-181: r=0.167, p=0.001), and WMS-delayed recall (t-tau: r=-0.237, p<0.001 and p-tau-181: r=-0.235, p<0.001). In the AD cohort, no statistically significant relationships were observed between CSF amyloid-β Discussion: The findings suggest that the relationship between CSF biomarkers and cognitive performance is strongest in MCI. The lack of significant correlations in the AD cohort may indicate other pathophysiological changes dominating cognitive dysfunction at this disease stage. Both tau and amyloid showed similar utility in reflecting cognitive impairment, in contrast to some reports in the literature. Further research is warranted to explore biomarker longitudinal impacts and their predictive values across the spectrum of cognitive impairment.

Indexed as

Alzheimer’s Disease Neuroimaging InitiativeAmyloid-βMild cognitive impairmentMini-Mental State ExamMontreal Cognitive AssessmentPhosphorylated-taupreclinical diseaseTotal-tau

Identifiers

PMID41377994
PMCPMC12687842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.